United States· US:51759-414_ce170247-5614-44bc-88e0-89f515d9d8be
Ustekinumab-aekn
A medicinal product containing ustekinumab-aekn, registered in United States by Teva Pharmaceuticals USA, Inc..
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- USTEKINUMAB-AEKN
- Manufacturer
- Teva Pharmaceuticals USA, Inc.
- Country
- United States (US)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- July 26, 2026
Packs & prices · 2
- ndc1151759-414-32
- ndc1151759414321 TRAY in 1 CARTON (51759-414-32) / 1 SYRINGE, GLASS in 1 TRAY / 1 mL in 1 SYRINGE, GLASS
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Ustekinumab-aekn in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandABSIMKYAccord Healthcare S.L.U.
- BelgiumAbsimky 130 mgAccord Healthcare
- CzechiaFYMSKINAFormycon AG, Martinsried/Planegg
- SwedenFymskina 130 mg Koncentrat till infusionsvätska, lösningFormycon AG
- PolandAbsimkyAccord Healthcare S.L.U.
- IcelandFymskinaFormycon AG
- NetherlandsFymskina 130 mg concentraat voor oplossing voor infusieFormycon AG
- IrelandFymskina 130 mg Concentrate for solution for infusionFormycon AG
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Imuldosa, Uzpruvo
- Iceland · Fymskina, Imuldosa
- Liechtenstein · Fymskina, Imuldosa
- Norway · Fymskina, Imuldosa
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/1fcc6c6c-5d72-4b02-9deb-85401a630369 GET /v1/drugs/1fcc6c6c-5d72-4b02-9deb-85401a630369?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "SUBCUTANEOUS",
"source": "ndc",
"strength": "90",
"substance": "USTEKINUMAB-AEKN",
"productndc": "51759-414",
"dosage_form": "INJECTION, SOLUTION",
"dea_schedule": null,
"strength_unit": "mg/mL",
"application_number": "BLA761343",
"marketing_category": "BLA"
}See everything about ustekinumab-aekn.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.